

The ISME Journal

Intestinal persistence of *Bifidobacterium infantis* is determined by interaction of host genetics and antibiotic exposure

--Manuscript Draft--

Manuscript Number:	ISMEJ-D-24-00338R3
Full Title:	Intestinal persistence of <i>Bifidobacterium infantis</i> is determined by interaction of host genetics and antibiotic exposure
Article Type:	Original Article
Keywords:	Microbiome, secretor status, $\alpha(1,2)$ -fucosylated glycans, <i>Bifidobacterium</i> , <i>Bifidobacterium infantis</i>
Corresponding Author:	Geraint Rogers SAHMRI: South Australian Health and Medical Research Institute Adelaide, AUSTRALIA
Corresponding Author's Institution:	SAHMRI: South Australian Health and Medical Research Institute
Other Authors:	Yiming Wang Jocelyn Choo Alyson Richard Lito Papanicolas Steve Wesselingh Steven Taylor
Abstract:	<p>Probiotics have gained significant attention as a potential strategy to improve health by modulating host-microbe interactions, particularly in situations where the normal microbiota has been disrupted. However, evidence regarding their efficacy has been inconsistent, with considerable inter-individual variability in response. We aimed to explore whether a common genetic variant that affects the production of mucosal $\alpha(1,2)$-fucosylated glycans, present in around 20% of the population, could explain the observed interpersonal differences in the persistence of commonly used probiotics. Using a mouse model with varying $\alpha(1,2)$-fucosylated glycans secretion (Fut2WT or Fut2KO), we examined the abundance and persistence of <i>Bifidobacterium</i> strains (<i>infantis</i>, <i>breve</i> and <i>bifidum</i>). We observed significant differences in baseline gut microbiota characteristics between Fut2WT and Fut2KO littermates, with Fut2WT mice exhibiting enrichment of species able to utilise $\alpha(1,2)$-fucosylated glycans. Following antibiotic exposure, only Fut2WT animals showed persistent engraftment of <i>Bifidobacterium infantis</i>, a strain able to internalise $\alpha(1,2)$-fucosylated glycans, while <i>B. breve</i> and <i>B. bifidum</i>, which cannot internalise $\alpha(1,2)$-fucosylated glycans, did not exhibit this difference. In mice with an intact commensal microbiota, the relationship between secretor status and <i>B. infantis</i> persistence was reversed, with Fut2KO animals showing greater persistence compared to Fut2WT. Our findings suggest that the interplay between a common genetic variation and antibiotic exposure plays a crucial role in determining the dynamics of <i>B. infantis</i> in the recipient gut, which could potentially contribute to the observed variation in response to this commonly used probiotic species.</p>
Additional Information:	
Question	Response
Please state the numeric word count of your manuscript, counting from the beginning of the abstract to the end of the main manuscript (excluding references and figure legends). If substantially longer than the limit (e.g., 5,000 words for an Article), you may be asked to reduce the	4927

manuscript's length, before or after review. Word counts for various publication types are detailed in our Author Instructions .	
Please confirm that all primary/secondary data and software code underlying this manuscript is available to reviewers during the peer review process. For example, are nucleic acid sequences available in a database and an accession number included in the manuscript? For more details about data availability, please see our Instructions to Authors page .	Yes
Has this manuscript been submitted to this journal previously?	No
<p>Do you or your co-authors have any conflict of interest? As corresponding author it is your responsibility to confirm with your co-authors whether they have any conflicts to declare. If unable to confirm, you will need to co-ordinate the completion of written forms from all co-authors and submit these to the editorial office before the manuscript is accepted.</p> <p>If you are in any doubt what constitutes a conflict, please read the FAQs or contact the editorial office.</p>	No



Dear ISME J Editorial team,

On behalf of all authors, please find our revised manuscript entitled "*Intestinal persistence of Bifidobacterium infantis is determined by interaction of host genetics and antibiotic exposure*" submitted for consideration to *The ISME Journal*.

We have carefully addressed the final recommendations provided by Editor-in-chief and Senior Editor. Each of the requested changes are presented in blue (e.g., **C1**), followed by our response in black (e.g., **R1**).

All authors have contributed to the manuscript and this revision and have seen and approved the final version.

Thank you for considering our manuscript for publication.

Sincerely,



Prof. Geraint Rogers
Microbiome and Host Health, South Australian Health and Medical Research Institute
College of Medicine and Public Health, Flinders University
geraint.rogers@sahmri.com

Editor-in-chief (Jillian Petersen)

C1: Based on the final recommendation of Senior Editor Richard Lamont, and on behalf of the International Society for Microbial Ecology, I am very pleased to inform you that your manuscript ISMEJ-D-24-00338R2 entitled "Intestinal persistence of Bifidobacterium infantis is determined by interaction of host genetics and antibiotic exposure" has been provisionally accepted for publication in The ISME Journal.

As the corresponding author of this manuscript, please make sure you complete the tasks below at your earliest convenience. Please note that we won't be able to officially confirm acceptance of your manuscript and proceed with the publication process until all requests have been addressed and all forms have been returned.

R1: Thank you very much for your positive feedback and for provisionally accepting our manuscript, ISMEJ-D-24-00338R2, entitled "Intestinal persistence of Bifidobacterium infantis is determined by interaction of host genetics and antibiotic exposure," for publication in The ISME Journal.

We are pleased with the decision and appreciate the time and effort the reviewers and editors have put into evaluating our work. We will ensure that all the necessary tasks are completed promptly to facilitate the final acceptance and publication process.

Specific Edits:

C2: "MiSeq Sequencing System" should be "MiSeq System" - please revise before uploading final files.

R2: Revised accordingly (Line 208).

C3: Files must not contain highlighting or tracked changes..

R3: All files have been reviewed and confirmed to be free of highlighting and tracked changes.

C4: References should quote all authors for papers with up to six authors; for papers with more than six authors, only the first six should be quoted followed by et al..

R4: We have revised the references to ensure that papers with up to six authors list all authors, while those with more than six authors list the first six followed by "et al.".

C5: Figure and table legends must be included at the end of article file, after the references.

R5: We have reviewed and confirmed that the figure and table legends are already included at the end of the article file, following the references.

C6: Figure files must be uploaded as individual files and then included in the merged file, ensuring that figures with multiple panels are uploaded as one file (e.g. Fig. 1A, 1B uploaded as Fig. 1).

R6: We have reviewed and confirmed that the figures have already been merged as individual figure panels before submission, with each multi-panel figure uploaded as a single file.

C7: Tables must be editable and either uploaded as separate files or included in the article file, after the references.

R7: We confirmed that no tables were drafted for the main article; hence, no tables will be included in the article file.

C8: All supplementary information, including supplementary figure and table legends, must be uploaded separately and not included in the article file.

R8: All supplementary information, including supplementary figure and table legends, has been uploaded in a separate file and will not be included in the article file.

C9: Provide a copy of your manuscript as a word document.

R9: A copy of word document is provided.

C11: Include a short running title of 40 characters or less including spaces.

R11: We have provided a short running title, “Fut2 impacts probiotic persistence,” under the main title of the article.

Intestinal persistence of *Bifidobacterium infantis* is determined by interaction of host genetics and antibiotic exposure

Running title: *FUT2* impacts probiotic persistence

Yiming Wang^{1,2}, Jocelyn M Choo^{1,2}, Alyson C Richard^{1,2}, Lito E Papanicolas^{1,2,3}, Steve L Wesselingh¹, Steven L Taylor^{1,2#}, Geraint B Rogers^{1,2#*}

¹ Microbiome and Host Health Programme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.

² Infection and Immunity, Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia.

³ SA Pathology, SA Health, Adelaide, South Australia, Australia.

[#] These authors share senior authorship.

*** Correspondence:**

Professor Geraint Rogers

Director, Microbiome & Host Health, South Australian Health and Medical Research Institute, North Terrace, Adelaide, SA 5001, Australia.

Email: geraint.rogers@sahmri.com

Phone: +61 (0)403 558251

ABSTRACT

Probiotics have gained significant attention as a potential strategy to improve health by modulating host-microbe interactions, particularly in situations where the normal microbiota has been disrupted. However, evidence regarding their efficacy has been inconsistent, with considerable inter-individual variability in response. We aimed to explore whether a common genetic variant that affects the production of mucosal $\alpha(1,2)$ -fucosylated glycans, present in around 20% of the population, could explain the observed interpersonal differences in the persistence of commonly used probiotics. Using a mouse model with varying $\alpha(1,2)$ -fucosylated glycans secretion (*Fut2*^{WT} or *Fut2*^{KO}), we examined the abundance and persistence of *Bifidobacterium* strains (*infantis*, *breve*, and *bifidum*). We observed significant differences in baseline gut microbiota characteristics between *Fut2*^{WT} and *Fut2*^{KO} littermates, with *Fut2*^{WT} mice exhibiting enrichment of species able to utilise $\alpha(1,2)$ -fucosylated glycans. Following antibiotic exposure, only *Fut2*^{WT} animals showed persistent engraftment of *Bifidobacterium infantis*, a strain able to internalise $\alpha(1,2)$ -fucosylated glycans, whereas *B. breve* and *B. bifidum*, which cannot internalise $\alpha(1,2)$ -fucosylated glycans, did not exhibit this difference. In mice with an intact commensal microbiota, the relationship between secretor status and *B. infantis* persistence was reversed, with *Fut2*^{KO} animals showing greater persistence compared to *Fut2*^{WT}. Our findings suggest that the interplay between a common genetic variation and antibiotic exposure plays a crucial role in determining the dynamics of *B. infantis* in the recipient gut, which could potentially contribute to the observed variation in response to this commonly used probiotic species.

Keywords

Microbiome, secretor status, $\alpha(1,2)$ -fucosylated glycans, *Bifidobacterium*, *Bifidobacterium infantis*

INTRODUCTION

Host-microbiome interactions play a pivotal role in shaping human physiology. The intestinal microbiome in particular is an important regulator of innate and adaptive immunity [1], metabolic control [2], the central nervous system [3], as well as contributing to energy and nutrient harvest [4], and suppressing pathogen proliferation [5]. Given the association between disruption of the commensal gut microbiota and adverse outcomes, there is significant interest in approaches that facilitate its restoration following perturbation. Among the most well-established of these approaches is the ingestion of viable commensal bacteria in the form of probiotics.

Probiotics can be defined as “live microorganisms, which when administered in adequate amounts, confer a health benefit on the host” [6]. Most commonly, these take the form of individual strains or multi-strain consortia, of well-characterised commensal bacteria, prepared either as liquid suspensions or in freeze-dried capsules. The principal concept underlying the use of probiotics is that the introduction of live bacteria can re-establish physiological homeostasis by modifying the composition or behaviour of the gut microbiota, or by directly providing regulatory cues to the host. Despite substantial evidence supporting the efficacy of probiotics in principle, their use remains poorly supported by empirical data in many physiological or health contexts [7, 8]. Further, substantial inter-individual variance in probiotic persistence has been noted, in part explained by variation in colonisation resistance by the microbiome [9, 10]. Consequently, the global probiotics market, which is projected to reach USD 73.9 billion by 2030 [11], is dominated by direct-to-consumer sales, with little or no consideration is given to recipient traits that might substantially influence probiotic efficacy.

Various mechanisms enable the human gut to regulate commensal microbiota composition. One of the principal mechanisms involves the secretion of specific types of sugars that are utilised by beneficial microbial species. Many mucosal constituents and secreted factors are decorated with glycans (oligosaccharides), that are added by a diverse family of glycosyltransferase enzymes [12]. Of these, the *FUT2* gene encodes a galactoside $\alpha(1,2)$ -fucosyltransferase, which adds a L-fucose monosaccharide to non-reducing end Gal residues to form Fuc $\alpha 1$ -2Gal-O-R glycans, termed the H antigens [13, 14]. Expressed by multiple mucosal epithelial cell types, this H antigen, is a highly versatile structure that can be further modified to form many other important glycans, including the AB blood group glycans. Because *FUT2* controls the nature of the various $\alpha(1,2)$ -fucosylated glycans secreted by mucosal surfaces, it is commonly referred to as the “secretor” gene [13].

Across the human population, multiple nonsense single nucleotide polymorphisms (SNPs) are found within the *FUT2* gene [15], leading to a “non-secretor” phenotype. The non-secretor phenotype, like the AB blood groups, is one of the more common functional mutations maintained in the population, with approximately one-fifth of people carrying homozygous loss-of-function *FUT2* genes [15]. This high carriage of loss-of-function mutations is likely a result of positive selection from altered susceptibility to infections by certain bacterial and viral pathogens [16]. However, as fucosylated glycans are an important nutrient source for gut microbes, their absence in non-secretors has been shown to influence the composition of commensal microorganisms [16, 17].

The intact commensal microbiota of secretor individuals is likely to be enriched for glycan utilising bacteria. In contrast, depletion of commensal taxa, for example, through antibiotic exposure, can provide a selective advantage to exogenous glycan utilisers that are absent in

non-secretors [9, 18]. Probiotic preparations typically contain *Bifidobacteria* (*Bifidobacterium adolescentis*, *animalis*, *bifidum*, *breve*, and *longum*) and/or Lactobacilli (*Lactobacillus acidophilus*, *casei*, *fermentum*, *gasseri*, *johnsonii*, *paracasei*, *plantarum*, *rhamnosus*, and *salivarius*). Both genera include species that encode the specific glycoside hydrolases (GHs), GH29, GH95, and GH151, which can utilise the H antigen. However, both genera also include species without this glycoside hydrolase capacity. Therefore, the ability of a probiotic to colonise and persist in an individual may depend on the presence of secreted glycans and the ability of the introduced bacterial strain to utilize them. This is supported by studies identifying increased persistence of such glycan-utilising species when supplemented with exogenous oligosaccharides [19, 20].

We hypothesised that the interplay between secretor status, the glycan utilisation ability of the probiotic strain, and the presence of a disrupted commensal microbiota due to antibiotic exposure, would collectively influence the abundance and persistence of probiotic populations in the gut. To test this hypothesis, we introduced probiotic *Bifidobacterium* strains into a murine model of secretor/non-secretor status, with or without prior antibiotic depletion of commensal microbiota.

MATERIALS AND METHODS

Details of reagent catalogue numbers and resource links are provided in **Supplementary Table S1**.

Mouse model

Establishment of a Fut2 knockout mice

A *Fut2*^{KO} mouse line was developed using CRISPR/Cas9 technology in C57BL/6 mice (IMSR_JAX:000664) by South Australian Genome Editing (SAGE). Briefly, a 1230 bp region of the *Fut2* exon region was excised using targeted CRISPR guide sequences. Gene knock out was confirmed by Sanger sequencing and phenotype confirmed by $\alpha(1,2)$ -fucosylated glycan staining of intestinal biopsies using Ulex Europaeus lectin 1 (**Supplementary Fig. S1**), as described previously [21]. Littermate *Fut2*^{WT} and *Fut2*^{KO} mice (six weeks of age, gender-matched) were obtained by mating heterozygous male and female mice originating from F1 heterozygotes.

Breeding and housing

All mice were bred and maintained under specific and opportunistic pathogen free (SPF) conditions at 22°C \pm 2°C, under a 12 h light-dark cycle, at the South Australian Health and Medical Research Institute (SAHMRI). All mice were housed in individually ventilated cages, fed an identical diet (Teklad Global 18% Rodent Protein Diet, Envigo, Huntingdon, UK), maintained under the Federation of European Laboratory Animal Science Associations (FELASA) standards and routinely screened using a SNP genotyping panel.

Heterozygous x heterozygous breeding was performed to allow for *Fut2*^{KO} and *Fut2*^{WT} littermates, while also standardising effects of *Fut2* that occur through vertical transmission.

Fut2^{KO}, *Fut2*^{HET}, and *Fut2*^{WT} littermates were co-housed from birth until weaning (~3 weeks), where they were genotyped by PCR amplicon melt curve using primers targeting the outer and inner regions of the *Fut2* gene. *Fut2*^{KO} and *Fut2*^{WT} mice separated into cages after weaning based on sex and *Fut2* genotype (**Figure 1A**). No experiments were performed on *Fut2*^{HET} mice. In all experiments, 6-week old, age- and sex-matched mice were used. Each experimental group consisted of at least 4 cages to control for cage effects. Given the heterogeneous nature of the gut microbiome, each mouse was considered as a biological replicate rather than a technical replicate, even within cohoused littermates.

Antibiotic treatment

A cocktail of ampicillin (1 g/L, Sigma-Aldrich) and neomycin (0.5 g/L, Sigma-Aldrich) was provided to mice via drinking water for 7 days. Water bottle volume and mouse weight were monitored to assess water intake. Antibiotic activity was confirmed by qPCR targeting 16S rRNA gene (**Supplementary Table S2**) of faecal samples at day 7.

Probiotic supplementation

Mice received 5×10^7 colony forming units (CFU)/g of mouse of either *B. infantis*, *B. bifidum*, or *B. breve* daily for 5 days via oral gavage. A starting gavage concentration of 5×10^9 CFU/mL in PBS was prepared daily from fresh overnight cultures. The dose was selected based on previous reports of safety, persistence, and immune modulation capability [22, 23].

Bacterial strains

B. bifidum JCM 1255 (ATCC equivalent: 29521), *B. longum subspecies infantis* JCM 1222 (ATCC equivalent: 15697), *B. breve* JCM 1192 (ATCC equivalent: 15700) were obtained from the Japan Collection of Microorganisms (JCM; RIKEN, Saitama, Japan). Utilisation of

α (1,2)-fucosylated glycans was assessed by *in vitro* culture in mBasal media with/without supplementation of 5% w/v 2'-fucosyllactose (Layer Origin, Ithaca, New York, USA) (**Supplementary Fig. S2**). This was confirmed by existing literature [24, 25] and the Carbohydrate-Active enZymes (CAZy) database [26] showing that *B. bifidum* JCM 1255 encodes external GH29 and GH95 α -1,2-L-fucosidases, but does not consume fucose as a carbon source [27], *B. infantis* JCM 1222 encodes intracellular GH29, GH95, and GH151 α -1,2-L-fucosidases along with glycan transporters, and *B. breve* JCM 1192 encodes only the GH95 family.

Faecal and tissue collection

At least two faecal pellets were collected from separated mice at the beginning of the light phase, unless specified otherwise. For intestinal tissue collection, mice were sacrificed by CO₂ asphyxiation and laparotomy was immediately performed using a vertical midline incision. Once the digestive tract was exposed, separate dissection tools were used to dissect tissue into four parts: the proximal small intestine; distal small intestine; caecum; and large intestine. For small and large intestine tissue segments, the luminal content was collected by instilling sterile PBS using a syringe barrel and the flushed mucosal tissue was collected into separate tubes. All collected faecal samples, organs, and luminal contents were immediately frozen on dry ice and stored at -80°C until further processing.

DNA extraction

DNA extraction of faecal samples

Faecal pellets were weighed, and 25 mg samples (± 10 mg) were resuspended in 300 μ L of cold phosphate buffered saline (PBS) (pH 7.2) by vortexing and pelleted by centrifugation at $10,000 \times g$ for 10 min at 4°C. Microbial DNA was extracted from faecal samples using the

PowerLyzer PowerSoil DNA Isolation Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions as described previously [28].

DNA extraction on mucosal tissue samples

Mucosal tissue from the proximal small intestine, distal small intestine, and large intestine were semi defrosted, and 3 cm was removed from the tissue centre using sterile scalpel. The dissected tissues were cut open longitudinally and mixed with 750 μ L PowerSoil bead solution, and 60 μ L solution C1 in a PowerSoil bead tube. The bead tube was then incubated at 65°C for 10 mins prior to bead beating. The subsequent DNA isolation was performed using the PowerLyzer PowerSoil DNA Isolation Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions as described previously [28].

16S rRNA gene amplicon sequencing and bioinformatic processing

Amplicon libraries of the V4 hypervariable region for 16S rRNA gene were prepared from DNA extracts using modified universal bacterial primer pairs 515F and 806R [29]. Amplicon libraries were indexed, cleaned, and sequenced according to the 16S Metagenomic Sequencing Library Preparation protocol. Paired-end sequencing was performed using MiSeq Reagent Kit v3 (600-cycle kit) (Illumina) on a MiSeq System (Illumina), at the South Australian Genomics Centre (SAGC). Paired-end 16S rRNA gene sequence reads were analysed using QIIME2 version 2021.11.0 [30]. Briefly, de-noising was performed on de-multiplexed sequences using the DADA2 plugin [31], resulting in a mean read depth of $15,563 \pm 2,719$ for stool and $6,941 \pm 4,503$ for tissue. Taxonomic classification of amplicon sequence variants (ASVs) was performed based on the V4 hypervariable region of the SILVA 16S rRNA gene reference database (version 138) at 99% similarity [32]. Sufficient coverage at this depth is confirmed by the rarefaction curve, which reached an asymptote.

Sequence data has been deposited in the NCBI SRA under accession number
PRJNA1011386.

Microbiota characterisation

The taxonomic relative abundance at the genus level was used to generate alpha diversity (within-group) and beta diversity (between-group) measures. Alpha diversity metrics (observed ASVs, Pielou's evenness, Shannon diversity, and Faith's phylogenetic diversity) were obtained from QIIME2 at sampling depth of 9,883 reads (faecal samples) and 662 reads (mucosal tissue samples). The Bray-Curtis dissimilarity index was calculated to compare microbiome similarity between groups (beta diversity), using square-root transformed species relative abundance data using the 'vegan' package in R. Non-metric multidimensional scaling (nMDS) for all beta diversity measures were generated using the 'vegan' package in R. Core taxa were defined as those present in more than 95% of samples, with a mean relative abundance of >0.01%. Identification of taxa with α -1,2-L-fucosidases capability was determined by comparing the genus-level taxonomic classification to genomes identified by CAZy [26] as carrying either the GH29, GH95, or GH151 enzyme families.

Quantification of *Bifidobacterium* species and total bacterial load

We investigated the extent to which 16S amplicon sequencing could discriminate between different *Bifidobacterium* species. As expected, level 7 resolution (species-level output) was unable to differentiate bifidobacterial strains, reflecting a well-recognised limitation of this approach. Given that, quantification of total bacterial load, *B. breve*, *B. infantis*, and *B. bifidum* was performed by SYBR Green-based qPCR assays (**Supplementary Table S2**). For all qPCR assays, 1 μ L of DNA template was combined with 0.7 μ L of 10 μ M forward primer, 0.7 μ L of 10 μ M reverse primer, 17.5 μ L of 2 \times SYBR Green (Applied Biosystems,

Waltham, Massachusetts, USA), and 15.1 μ L nuclease-free water. All samples were run in triplicate (10 μ L each replicate). Gene copy quantification was performed using a standard curve generated from a known concentration of a pure colony control. Any sample with a cycle threshold (CT) \geq 40 cycles was defined as 40 (limit of detection).

Culture of *Bifidobacterium* strains

All *Bifidobacterium* strains used in this study were cultured in De Man, Rogosa and Sharpe (Becton Dickinson, Franklin Lakes, NJ, USA) broth or agar supplemented with 0.34% (w/v) sodium ascorbate and 0.02% (w/v) cysteine-HCl (MRS-CS) and were grown under anaerobic conditions (75% N₂, 20% CO₂, 5% H₂, Coy Laboratory Products, Grass Lake, Michigan, USA) at 37 °C. The growth of *Bifidobacterium* was measured by optical density (OD₆₀₀) using multimode plate reader (PerkinElmer, Waltham, Massachusetts, USA).

***In vitro* glycan utilisation assay**

Faecal pellets from untreated WT mice were incubated in mBasal media (mBasal; 10 g/L Trypton, 2 g/L yeast extract, 5 g/L NaCl, 0.2 g/L magnesium sulfate, 2 g/L dipotassium hydrogen phosphate, pH 6.4) with/without supplementation of 5% w/v of 2'-Fucosyllactose (Layer Origin, Ithaca, New York, USA) at 37°C under strict anaerobic conditions (75% N₂, 20% CO₂, 5% H₂, Coy Laboratory Products, Grass Lake, Michigan, USA). Bacterial biomass was measured by optical density (OD₆₀₀) using multimode plate reader (PerkinElmer, Waltham, Massachusetts, USA). Bacterial colonies cultured from faecal samples were identified by matrix assisted laser desorption/ionization time-of-flight (MALDI-TOF) (Billerica, Massachusetts, United States), as described previously [33].

Statistical analysis

266 Experimental mice were randomly assigned to different treatment groups. The investigators
267 were not blinded to the experimental groups. No outliers have been removed from any of the
268 data presented. All data analyses were performed using either R (R Foundation for Statistical
269 Computing; version 4.1.0) or GraphPad Prism software (GraphPad Software, Inc.; version
270 9.00). For parametric data, unpaired Student's *t* test was used to compare data between two
271 unpaired groups; One-way ANOVA was used to compare data among three or more unpaired
272 groups. For non-parametric data, Mann-Whitney *U* test was used to compare data between
273 two unpaired groups; Kruskal-Wallis test was used to compared data among three or more
274 unpaired groups. Differences in Bray-Curtis dissimilarity between groups was performed by
275 permutational multivariate ANOVA (PERMANOVA) and pairwise PERMANOVA, using
276 the "adonis" package in R, with 9,999. Linear discriminant analysis Effect Size (LEfSe) was
277 applied to identify the abundant taxa in each site, using default parameters [34]. Area under
278 the curve (AUC) was calculated for *in vitro* growth experiments (using OD₆₀₀ values) and
279 bifidobacterial persistence in mice (using copies/ng faecal DNA). Log-rank test was
280 employed to compare survival time differences based on bacterial qPCR detection. One-
281 tailed tests were used where differences between groups were hypothesised to be in a single
282 direction. Statistical outcomes with *P* value <0.05 were considered statistically significant.
283 Core taxa plot was generated using GraphPad Prism, other data were visualised using R.

RESULTS

Fut2 shapes the faecal microbiota

Assessment of the faecal microbiota between SPF *Fut2*^{WT} and *Fut2*^{KO} littermates was performed at 6 weeks of age in both male and female mice (**Fig. 1A**). Faecal microbiota composition (**Fig. 1B**) differed significantly between *Fut2*^{WT} and *Fut2*^{KO} littermates (PERMANOVA: $R^2=0.028$; $P=0.028$, **Fig. 1C**) when male and female mice were assessed together. However, stratification according to sex identified a greater divergence according to genotype in male mice (PERMANOVA: $R^2=0.12$; $P=0.021$) compared to female mice (PERMANOVA: $R^2=0.037$; $P=0.38$, **Fig. 1C**). Exploration of this sex effect identified a significant interaction between sex and *Fut2* genotype (PERMANOVA: $R^2=0.11$; $P=0.0068$, **Supplementary Table S3**). These findings were unchanged after adjustment for cage effects (**Supplementary Table S3**). Given the interaction between sex and genotype, all subsequent experiments involved male mice only.

Potential relationships between secretor status and microbiota characteristics were then explored. While bacterial alpha-diversity measures did not differ substantially between *Fut2*^{WT} and *Fut2*^{KO} groups (**Supplementary Fig. S3**), the membership of core microbiota (taxa present in $\geq 95\%$ of samples at $\geq 0.01\%$) did (**Fig. 1D**). Specifically, *Oscillospiraceae* (unassigned) were exclusively core in *Fut2*^{WT}, whereas *Bifidobacterium*, *Clostridia* (UCG014), *Lachnoclostridium*, and *Parabacteroides* were exclusively core in *Fut2*^{KO} mice (**Fig. 1E**). Three bacterial genera had a significantly higher relative abundance in *Fut2*^{WT} mice, whereas 13 were more prevalent in *Fut2*^{KO} mice (**Fig. 1F**). Of these, *Lactobacillus*, a genus with GH29 and GH151 that comprise α -1,2-L-fucosidases (**Supplementary Table S4**), was more abundant in *Fut2*^{WT} (LDA score [\log_{10}]=4.88).

Together, these findings support previous reports of a relationship between *Fut2* and faecal microbiome characteristics.

Distal small intestine microbiota influenced by *Fut2*

As *Fut2* is differentially expressed throughout the gastrointestinal tract [35], we then compared microbiota characteristics in tissue from the proximal small intestine, the distal small intestine, and the large intestine between *Fut2*^{WT} and *Fut2*^{KO} mice (**Fig. 2A**).

Microbiota composition differed significantly between *Fut2*^{WT} and *Fut2*^{KO} groups in the distal small intestine (PERMANOVA: $R^2=0.54$; $P=0.0071$, **Fig. 2B**), coinciding with inducible *Fut2* expression, but not in the proximal small intestine (PERMANOVA: $R^2=0.19$; $P=0.13$, **Fig. 2B**) or the large intestine (PERMANOVA: $R^2=0.16$; $P=0.18$, **Fig. 2B**).

Taxonomic assessment identified that *Candidatus* Arthromitus (LDA score [\log_{10}]=5.43) was more abundant in the distal small intestine in *Fut2*^{WT} compared to *Fut2*^{KO} mice, whereas *Lachnospiraceae* (unassigned) and *Acetatifactor* were more abundant in the large intestine of *Fut2*^{WT} compared to *Fut2*^{KO} mice (LDA score [\log_{10}]=4.35, and LDA score [\log_{10}]=3.93, respectively) (**Fig. 2C**).

***Fut2*-microbiota relationships can be recapitulated *in vitro* through glycan exposure**

To further investigate the relationship between $\alpha(1,2)$ -fucosylated glycans and intestinal microbiology, faecal homogenate from *Fut2*^{WT} mice was grown in a mBasal media with or without the $\alpha(1,2)$ -fucosylated glycan, 2'-FL. Microbiota assessment following *in vitro* culture (**Fig. 3A**) confirmed the findings of the *in vivo* faecal microbiota analysis, with a significant difference in Bray-Curtis similarity between faecal cultures with and without 2'-FL (PERMANOVA: $R^2=0.90$; $P<0.0001$, **Fig. 3B**). This difference was marked by an

enrichment of glycan-utilising genera (*Bacteroides*, *Enterococcus*, *Lactobacillus*), with compensatory decreases in the relative abundance of other taxa (**Fig. 3C**).

Analysis involving inoculation of solid basal media, either alone or supplemented with 2'-FL, with faecal homogenate from *Fut2^{WT}* mice further supported these findings. Specifically, proportional colony counts (**Supplementary Fig. S4, Supplementary Table S5**) showed 2'-FL led to enrichment of *Enterococcus faecalis* (66% with 2'-FL vs 4% without 2'-FL) and *Lactobacillus murinus/reuteri* (18% with 2'-FL vs 1% without 2'-FL), with a corresponding decrease in *E. coli* (16% with 2'-FL vs 95% without 2'-FL) (**Fig. 3D**). Enrichment of bacteria with 2'-FL supplementation was further confirmed by increased growth rate and bacterial density (median AUC_[mBasal]=15.1 [IQR=14.3, 16.5]; AUC_[mBasal+2'-FL]=35.6 [33.3, 38.7]; $P<0.0001$, **Fig. 3E**).

We investigated whether differences in microbiota composition between *Fut2^{WT}* and *Fut2^{KO}* mice reflected selection for bacterial populations able to utilise $\alpha(1,2)$ -fucosylated glycans for growth in *Fut2^{WT}* animals. Faecal homogenates from *Fut2^{WT}* and *Fut2^{KO}* mice were used to inoculate mBasal media with or without 2'-FL supplementation. The increase in bacterial density between 2'-FL supplemented media and media alone was significantly greater when faecal homogenates were derived from *Fut2^{WT}* compared to *Fut2^{KO}* mice (median AUC_[WT]=20.5 [IQR=16.6, 23.5]; AUC_[KO]=16.7 [13.1, 19.7]; $P=0.0051$, **Fig. 3F**), consistent with a greater abundance of glycan-utilizing bacteria.

Probiotic bifidobacterial species differentially colonise *Fut2^{WT}* and *Fut2^{KO}* mice

Based on the relationship between host glycan production and gut microbiota composition, we hypothesised that the colonisation dynamics (abundance and persistence) of

bifidobacterial probiotic species, introduced following antibiotic depletion, would differ between *Fut2*^{WT} and *Fut2*^{KO} recipients (**Fig. 4A**). We utilised strains of three *Bifidobacterium* species that interact with glycan in different ways; *B. infantis*, an intracellular $\alpha(1,2)$ -fucosylated glycan-utiliser, *B. bifidum*, an extra-cellular $\alpha(1,2)$ -fucosylated glycan utiliser, and *B. breve*, a species that does not utilise $\alpha(1,2)$ -fucosylated glycans (characteristics that were confirmed by *in vitro* growth assays, **Supplementary Fig. S2**).

The persistence of species that do not internalise and degrade $\alpha(1,2)$ -fucosylated glycans (*B. bifidum* and *B. breve*) did not differ substantially when introduced to *Fut2*^{WT} or *Fut2*^{KO} mice (**Fig. 4B-4C**). In contrast, the abundance and persistence of *B. infantis*, an intracellular glycan utiliser, differed significantly according to the genotype of the recipient (**Fig. 4B-4C**). Ten days post-gavage, *B. infantis* was detected in 7 out of 8 *Fut2*^{WT} mice but 0 out of 8 *Fut2*^{KO} mice (Log-rank test: $\chi^2=11.4$; $P=0.00074$, **Fig. 4B**). The overall abundance of *B. infantis* was also significantly higher in *Fut2*^{WT} compared to *Fut2*^{KO} mice in the following 14 days post-gavage (mean AUC_[WT]=31.1 [SD=4.1]; AUC_[KO]=26.2 [5.2]; $P=0.028$, **Fig. 4C**).

A difference in *B. infantis* persistence was also evident in intestinal tissue assessed five days post-gavage. *B. infantis* was significantly more abundant in *Fut2*^{WT} large intestine (median *Fut2*^{WT}=log₁₀ 6.7 copies/g tissue [IQR=log₁₀ 6.0, log₁₀ 6.8]; *Fut2*^{KO}=log₁₀ 2.6 [IQR=log₁₀ 2.6, log₁₀ 3.9]; $P=0.011$), and numerically, though not significantly, more abundant in *Fut2*^{WT} proximal ($P=0.085$) and distal small intestine ($P=0.094$) (**Fig. 4D**).

Prior antibiotic exposure profoundly affects the *Fut2*-probiotic relationship

To test whether the relationship between *Fut2* genotype and probiotic strain characteristics were independent of antibiotic exposure, we supplemented non-antibiotic exposed mice with

B. infantis (**Fig. 5A**). No significant difference in *B. infantis* persistence post-gavage was observed between *Fut2*^{WT} and *Fut2*^{KO} mice (**Fig. 5B**), and *B. infantis* was not detectable in intestinal tissue from either *Fut2*^{WT} or *Fut2*^{KO} mice at day 5 post-gavage (**Supplementary Fig. S5A**). However, analysis of *B. infantis* abundance following gavage (based on AUC) revealed an effect that was opposite to that observed in antibiotic exposed mice, with *B. infantis* significantly higher in *Fut2*^{KO} mice compared to *Fut2*^{WT} (mean AUC_[WT]=3.8 [SD=0.6]; AUC_[KO]=5.6 [0.90]; $P=0.00046$; **Fig. 5C**).

Faecal levels of *Bifidobacterium* probiotics were assessed during the instillation period (samples collected two hours prior to gavage and six hours after gavage). Levels in post-gavage samples (6 hours) did not differ between *Fut2*^{WT} and *Fut2*^{KO} mice, consistent with the instillation of equal probiotic loads. However, at 22 hours post-gavage (2 hours prior to gavage), levels in *Fut2*^{KO} mice were significantly higher than in *Fut2*^{WT} mice ($P<0.0001$; **Supplementary Fig. S5B**). No cumulative effect was observed with repeat gavage and the decline in probiotic levels after 22 hours was comparable to that observed in the 24 hours post cessation of installation.

DISCUSSION

Although probiotics have shown great potential in modifying host-microbiome interactions [36], their actual performance has been disappointing in many clinical contexts [37]. Previous studies have investigated the reasons for this underperformance, relating to cohort-level effects and variation in response between individuals. Mode of delivery and dose have both been shown to contribute to overall efficacy [38, 39], whereas the habitual diet of the recipient, particularly fibre intake, is an important determinant of probiotic response [40]. The influence of factors that shape the gut microbiome on the abundance and persistence of probiotics is unsurprising [41, 42], given the ability of resident gut microbiota to competitively exclude introduced populations [10]. Indeed, exposure to antibiotics, a factor that greatly impacts the gut microbiome, has been shown to considerably influence probiotic effects at a microbiological level [9, 43]. However, while common *FUT2* genetic variants are known to help shape intestinal microbiology [16, 17], the effect of secretor status on probiotics had not been described.

Our study highlights several important points in relation to inter-individual variance in intestinal microbiology and probiotic efficacy. With 20% of the global population also homozygous for a non-functional *FUT2* gene [15], our findings suggest that these “non-secretor” individuals will also experience different probiotic population dynamics compared to “secretor” individuals, if the probiotic taken contains one of the many bacterial species able to utilise $\alpha(1,2)$ -fucosylated glycans (H antigens). In our study, this was reflected in the significantly greater transience of *B. infantis* in the faecal and intestinal microbiome of non-secretor (*Fut2*^{KO}) mice compared with secretor mice following antibiotic exposure.

Bifidobacterial species that are commonly used as probiotics are relatively close phylogenetically but differ in their ability to use glycans, even at a strain level [44]. We showed that neither *B. breve* (JCM 1192) nor *B. bifidum* (JCM 1255) differed in their abundance or persistence between secretor and non-secretor animals. In contrast, *B. infantis* (JCM 1222) persisted for significantly longer and showed a significantly higher abundance in secretor mice compared to non-secretor mice. This finding likely reflects differences in H antigen hydrolysis and catabolism capacities between species when administered as a probiotic. For example, *B. infantis* encodes GH29, GH95, and GH151 family intracellular α -1,2-L-fucosidases, along with fucose transporters to facilitate internalisation [44]. While independent hydrolysis and catabolism of mucin-bound H antigens by *B. infantis* is not hypothesised [25], cross-feeding by organisms with extracellular α -1,2-L-fucosidases is likely, even following antibiotic supplementation [45]. In contrast, *B. bifidum*, while expressing extracellular GH29 and GH95 α -1,2-L-fucosidases, does not consume fucose to facilitate growth [27]. Finally, *B. breve*, encodes a separate GH95 intracellular α -1,2-L-fucosidase along with fucose transporters. While this species is capable of utilising the H antigen with support from cross-feeding [46], these findings suggest reduced persistence compared with *B. infantis*, when administered as a probiotic.

We found that antibiotic exposure influenced the persistence of probiotics in a secretor status-dependent manner. In the absence of microbiota depletion through antibiotic exposure, it would be expected that other commensal bacteria would utilise available glycans within the secretor gut. Moreover, such strains are highly adapted to an individual's gut environment, making them likely to outcompete any exogenous glycan-utilisers that are introduced. When we explored this directly, we found that in the absence of a prior period of antibiotic exposure, the higher levels and greater persistence of *B. infantis* in secretors was inverted,

with these *B. infantis* being significantly higher in non-secretor mice. These findings likely reflect the competitive exclusion of H antigen-utilising probiotics in the secretor gut and highlight the importance of considering the ecological context in relation to probiotic impact.

It should be noted that our antibiotic mix contained a cocktail of ampicillin and neomycin, designed to deplete a wide range of bacteria. While most *Bifidobacterium* strains are resistant to neomycin, the tested strains are sensitive to ampicillin [47]. We designed the experiment so that gavage with *Bifidobacterium* was immediately after ceasing antibiotic depletion to maximize colonisation without competition from other bacteria. It is possible that residual antibiotics in the intestine deplete *Bifidobacterium* over the first days of gavage. For this reason, we performed gavage for 5 days, a time period that extends beyond the activity spectrum of the administered antibiotics. Such an antibiotic combination is common for mouse models [48, 49], as well as empiric for suspected sepsis in humans [50].

While this study was performed in mice, the effect of secretor status on bifidobacterium supplementation has important implications for probiotic strategies in humans. It is crucial to consider individual host traits and recent antibiotic exposure when designing a probiotic intervention [51]. The findings here suggest that the 20% of the population who are non-secretors may have poorer persistence of H antigen utilising probiotics, such as *B. infantis*, compared to secretors following antibiotic exposure. Conversely, in the absence of recent antibiotic exposure, higher levels of microbial niche occupancy in secretors may hamper *B. infantis* persistence compared to non-secretors. An individualised supplementation with prebiotics may have potential as a means to optimise probiotic uptake in non-secretors. For example, previous studies have shown that supplementation with human milk oligosaccharides can enhance *B. infantis* engraftment [20], with successful supplementation

shown to reduce intestinal inflammation in infants [52]. Investigating additional $\alpha(1,2)$ -fucosylated glycans, given as prebiotics, may lead to improved outcomes of *B. infantis* supplementation in non-secretor individuals.

Determining the impact of secretor status on other species commonly considered beneficial and marketed as probiotics is challenging due to their broad range of carbohydrate utilisation capabilities [53]. For instance, *Akkermansia muciniphila*, a mucin-degrading species, has been associated with a reduced risk of chronic inflammatory diseases in humans and mice [54], and is a potential target for probiotic development [51]. However, its utilisation of mucin glycoproteins, including the $\alpha(1,2)$ -fucosylated glycan, 2'-fucosyllactose [53], suggests that it may also be affected by secretor status. Although *Akkermansia* was not detected in the mice of this study, we found that *Candidatus* Arthromitus, another genus associated with immune modulation [55], was enriched in the distal small intestinal mucosal tissue of secretor mice. Genome annotation of *Candidatus* Arthromitus has indicated other fucose utilisation capabilities [56], indicating that the functional *FUT2* gene may promote colonisation by this species.

Our experiments involved SPF mice that were obtained through heterozygous mating. Such breeding was essential to allow comparison of *Fut2*^{WT} and *Fut2*^{KO} littermates from a maternal secretor lineage. The findings from this study are therefore independent of vertical transmission effects, which are known to influence the microbiome of the offspring [57, 58], and indicate that a change in gut microbiology occurred post-weaning. This difference in baseline gut microbiota composition between secretors and non-secretors was also only evident in male mice. The effect of sex on the relationship between secretor status and the gut microbiome is difficult to explain but may relate to variable intestinal expression of *Fut2*,

which can be altered factors such as stress [59]. In addition, independent interactions between sex hormones and the gut microbiome [60] may affect the relationship between *Fut2* and the gut microbiome.

We acknowledge the importance of considering blood antigens/ABO phenotypes in interpreting the influence of *FUT2* gene on the gut microbiome, as indicated by recent studies [61, 62]. Indeed, in humans, *FUT2* is responsible for the generation of the H antigen, which can be further modified to give the OLewis^b, ALewis^b, or BLewis^b antigens [63]. Each of these glycans can modulate the competitive advantage of particular microbes capable of cleaving the oligosaccharide constituents. In the absence of *FUT2*, these Lewis^b antigens are not displayed, leading to a Lewis^a antigen. While our study did not address these blood type variations, it should be noted that even in humans, a secretor O blood group and a non-secretor O blood group are not the same. The impact of this on the gut microbiome is evidenced by studies reporting an association between H antigen concentrations and gut microbiome characteristics [58].

Our study demonstrates a *Fut2*-dependent genetic determinant for inter-individual response to probiotic supplementation, which is affected by antibiotic exposure and glycan utilisation capabilities of the probiotic strain. With prior antibiotic exposure, *Fut2* functionality was associated with increased persistence of *B. infantis*, consistent with its ability to utilise the H antigen. However, without antibiotic exposure, *Fut2* functionality was associated with lower abundance of *B. infantis*, relating to difference in baseline microbiology and niche space occupation.

ACKNOWLEDGMENTS

We would like to thank Ms. Nicola Cornelius and Mr. Dylan Harnas from SAHMRI Bioresource for providing breeding and oral gavage service, and Ms. Furdosa Ababor for support with DNA extraction. We also extend our gratitude to Mr. Levi Elms for conducting qPCR on samples extracted from mouse intestinal tissues following Yiming Wang's graduation and relocation to another city.

YMW is supported by Flinders International Postgraduate Research Scholarship (FIPRS) and South Australia Health and Medical Research Institute (SAHMRI) research top-up scholarship. SLT is supported by an NHMRC Emerging Leadership grant (GNT2008625). GBR is supported by a National Health and Medical Research Council (NHMRC) Senior Research Fellowship (GNT119378) and a Matthew Flinders Professorial Fellowship.

AUTHOR CONTRIBUTIONS

The study was conceived by SW, SLT and GBR. YW, SLT, GBR and JMC designed the experiments. YW and SLT performed the experiments. YW and SLT undertook the data generation and statistical analysis. GBR, JMC, AR, and LEP provided technical support and guidance. YW, JMC, SLT, and GBR drafted the manuscript. All authors approved the final version of the manuscript.

DECLARATION OF INTERESTS

The authors declare that they have no competing interests, nor any financial or personal relationships with other people or organisations that could bias this study.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

545 All mice experiments were approved by the South Australia Health and Medical Research
546 Institute Animal Ethics Committee (application numbers SAM-21-07 and SAM-21-036).

547

548 **DATA AVAILABILITY STATEMENT**

549 All 16S rRNA gene sequencing data have been deposited to the NCBI SRA and are available
550 under accession number PRJNA1011386. All qPCR data is available through FigShare
551 (<https://figshare.com/s/9fa55ea8b65304d9f722>). Data processing, statistical analysis and
552 visualisation is available through GitHub (<https://github.com/Yiming-Wang-1992>).

REFERENCES

1. Zheng D, Liwinski T, Elinav E; Interaction between microbiota and immunity in health and disease. *Cell Res* 2020;**30**(6):492-506. doi: 10.1038/s41422-020-0332-7.
2. Agus A, Clement K, Sokol H; Gut microbiota-derived metabolites as central regulators in metabolic disorders. *Gut* 2021;**70**(6):1174-1182. doi: 10.1136/gutjnl-2020-323071.
3. Shoubridge AP, Choo JM, Martin AM, Keating DJ, Wong ML, Licinio J, et al.; The gut microbiome and mental health: advances in research and emerging priorities. *Mol Psychiatry* 2022;**27**(4):1908-1919. doi: 10.1038/s41380-022-01479-w.
4. Krajmalnik-Brown R, Ilhan ZE, Kang DW, DiBaise JK; Effects of gut microbes on nutrient absorption and energy regulation. *Nutr Clin Pract* 2012;**27**(2):201-14. doi: 10.1177/0884533611436116.
5. Kamada N, Chen GY, Inohara N, Nunez G; Control of pathogens and pathobionts by the gut microbiota. *Nat Immunol* 2013;**14**(7):685-90. doi: 10.1038/ni.2608.
6. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al.; Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat Rev Gastroenterol Hepatol* 2014;**11**(8):506-14. doi: 10.1038/nrgastro.2014.66.

- 576 7. Johnstone J, Meade M, Lauzier F, Marshall J, Duan E, Dionne J, et al.; Effect of
577 Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients: A
578 Randomized Clinical Trial. *JAMA* 2021;**326**(11):1024-1033. doi: 10.1001/jama.2021.13355.
579
- 580 8. Ong TG, Gordon M, Banks SS, Thomas MR, Akobeng AK; Probiotics to prevent
581 infantile colic. *Cochrane Database Syst Rev* 2019;**3**(3):CD012473. doi:
582 10.1002/14651858.CD012473.pub2.
583
- 584 9. Suez J, Zmora N, Zilberman-Schapira G, Mor U, Dori-Bachash M, Bashiardes S, et al.;
585 Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and
586 Improved by Autologous FMT. *Cell* 2018;**174**(6):1406-1423 e16. doi:
587 10.1016/j.cell.2018.08.047.
588
- 589 10. Zmora N, Zilberman-Schapira G, Suez J, Mor U, Dori-Bachash M, Bashiardes S, et al.;
590 Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with
591 Unique Host and Microbiome Features. *Cell* 2018;**174**(6):1388-1405 e21. doi:
592 10.1016/j.cell.2018.08.041.
593
- 594 11. Kabir SML, Islam SS, Tuhin Al F, Akhter AHMT; Production, Cost Analysis, and
595 Marketing of Probiotics. In: Amaresan N, Dharumadurai D, Babalola OOs (eds). *Food*
596 *Microbiology Based Entrepreneurship: Making Money From Microbes*. Singapore: Springer
597 Nature Singapore, 2023, 305-326.
598
- 599 12. Varki A; Sialic acids in human health and disease. *Trends Mol Med* 2008;**14**(8):351-
600 60. doi: 10.1016/j.molmed.2008.06.002.

13. Cooling L; Blood Groups in Infection and Host Susceptibility. *Clin Microbiol Rev* 2015;**28**(3):801-70. doi: 10.1128/CMR.00109-14.
14. Dotz V, Wuhrer M; Histo-blood group glycans in the context of personalized medicine. *Biochim Biophys Acta* 2016;**1860**(8):1596-607. doi: 10.1016/j.bbagen.2015.12.026.
15. Ferrer-Admetlla A, Sikora M, Laayouni H, Esteve A, Roubinet F, Blancher A, et al.; A natural history of FUT2 polymorphism in humans. *Mol Biol Evol* 2009;**26**(9):1993-2003. doi: 10.1093/molbev/msp108.
16. Taylor SL, McGuckin MA, Wesselingh S, Rogers GB; Infection's Sweet Tooth: How Glycans Mediate Infection and Disease Susceptibility. *Trends Microbiol* 2018;**26**(2):92-101. doi: 10.1016/j.tim.2017.09.011.
17. Lopera-Maya EA, Kurilshikov A, van der Graaf A, Hu S, Andreu-Sanchez S, Chen L, et al.; Effect of host genetics on the gut microbiome in 7,738 participants of the Dutch Microbiome Project. *Nat Genet* 2022;**54**(2):143-151. doi: 10.1038/s41588-021-00992-y.
18. Wacklin P, Makivuokko H, Alakulppi N, Nikkila J, Tenkanen H, Rabina J, et al.; Secretor genotype (FUT2 gene) is strongly associated with the composition of Bifidobacteria in the human intestine. *PLoS One* 2011;**6**(5):e20113. doi: 10.1371/journal.pone.0020113.
19. Heiss BE, Ehrlich AM, Maldonado-Gomez MX, Taft DH, Larke JA, Goodson ML, et al.; Bifidobacterium catabolism of human milk oligosaccharides overrides endogenous

competitive exclusion driving colonization and protection. *Gut Microbes* 2021;**13**(1):1986666.
doi: 10.1080/19490976.2021.1986666.

20. Button JE, Autran CA, Reens AL, Cosetta CM, Smriga S, Ericson M, et al.; Dosing a
synbiotic of human milk oligosaccharides and *B. infantis* leads to reversible engraftment in
healthy adult microbiomes without antibiotics. *Cell Host Microbe* 2022;**30**(5):712-725 e7. doi:
10.1016/j.chom.2022.04.001.

21. Taylor SL, Woodman RJ, Chen AC, Burr LD, Gordon DL, McGuckin MA, et al.; FUT2
genotype influences lung function, exacerbation frequency and airway microbiota in non-CF
bronchiectasis. *Thorax* 2017;**72**(4):304-310. doi: 10.1136/thoraxjnl-2016-208775.

22. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al.;
Commensal *Bifidobacterium* promotes antitumor immunity and facilitates anti-PD-L1
efficacy. *Science* 2015;**350**(6264):1084-9. doi: 10.1126/science.aac4255.

23. Pavan S, Desreumaux P, Mercenier A; Use of mouse models to evaluate the persistence,
safety, and immune modulation capacities of lactic acid bacteria. *Clin Diagn Lab Immunol*
2003;**10**(4):696-701. doi: 10.1128/cdli.10.4.696-701.2003.

24. Asakuma S, Hatakeyama E, Urashima T, Yoshida E, Katayama T, Yamamoto K, et al.;
Physiology of consumption of human milk oligosaccharides by infant gut-associated
bifidobacteria. *J Biol Chem* 2011;**286**(40):34583-92. doi: 10.1074/jbc.M111.248138.

25. Curiel JA, Peirotén Á, Landete JM, Ruiz de la Bastida A, Langa S, Arqués JL; Architecture Insight of Bifidobacterial α -L-Fucosidases. *International Journal of Molecular Sciences* 2021; doi: 10.3390/ijms22168462.
26. Cantarel BL, Coutinho PM, Rancurel C, Bernard T, Lombard V, Henrissat B; The Carbohydrate-Active EnZymes database (CAZy): an expert resource for Glycogenomics. *Nucleic Acids Res* 2009;**37**(Database issue):D233-8. doi: 10.1093/nar/gkn663.
27. Gotoh A, Katoh T, Sakanaka M, Ling Y, Yamada C, Asakuma S, et al.; Sharing of human milk oligosaccharides degradants within bifidobacterial communities in faecal cultures supplemented with *Bifidobacterium bifidum*. *Sci Rep* 2018;**8**(1):13958. doi: 10.1038/s41598-018-32080-3.
28. Choo JM, Rogers GB; Establishment of murine gut microbiota in gnotobiotic mice. *iScience* 2021;**24**(2):102049. doi: 10.1016/j.isci.2021.102049.
29. Choo JM, Leong LE, Rogers GB; Sample storage conditions significantly influence faecal microbiome profiles. *Sci Rep* 2015;**5**:16350. doi: 10.1038/srep16350.
30. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al.; Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. *Nat Biotechnol* 2019;**37**(8):852-857. doi: 10.1038/s41587-019-0209-9.

31. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP; DADA2: High-resolution sample inference from Illumina amplicon data. *Nat Methods* 2016;**13**(7):581-3. doi: 10.1038/nmeth.3869.
32. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, et al.; The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. *Nucleic Acids Res* 2013;**41**(Database issue):D590-6. doi: 10.1093/nar/gks1219.
33. Taylor SL, Leong LEX, Sims SK, Keating RL, Papanicolas LE, Richard A, et al.; The cystic fibrosis gut as a potential source of multidrug resistant pathogens. *J Cyst Fibros* 2021;**20**(3):413-420. doi: 10.1016/j.jcf.2020.11.009.
34. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al.; Metagenomic biomarker discovery and explanation. *Genome Biol* 2011;**12**(6):R60. doi: 10.1186/gb-2011-12-6-r60.
35. Bry L, Falk PG, Midtvedt T, Gordon JI; A model of host-microbial interactions in an open mammalian ecosystem. *Science* 1996;**273**(5280):1380-3.
36. Rauch M, Lynch SV; The potential for probiotic manipulation of the gastrointestinal microbiome. *Curr Opin Biotechnol* 2012;**23**(2):192-201. doi: 10.1016/j.copbio.2011.11.004.
37. Rijkers GT, de Vos WM, Brummer RJ, Morelli L, Corthier G, Marteau P; Health benefits and health claims of probiotics: bridging science and marketing. *Br J Nutr* 2011;**106**(9):1291-6. doi: 10.1017/S000711451100287X.

38. Bernatek M, Zukiewicz-Sobczak W, Lachowicz-Wisniewska S, Piatek J; Factors
Determining Effective Probiotic Activity: Evaluation of Survival and Antibacterial Activity of
Selected Probiotic Products Using an "In Vitro" Study. *Nutrients* 2022;**14**(16). doi:
10.3390/nu14163323.
39. Morelli L, Pellegrino P; A critical evaluation of the factors affecting the survival and
persistence of beneficial bacteria in healthy adults. *Benef Microbes* 2021;**12**(4):15-25. doi:
10.3920/BM2021.0017.
40. Holmes ZC, Villa MM, Durand HK, Jiang S, Dallow EP, Petrone BL, et al.; Microbiota
responses to different prebiotics are conserved within individuals and associated with habitual
fiber intake. *Microbiome* 2022;**10**(1):114. doi: 10.1186/s40168-022-01307-x.
41. Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, et
al.; Human gut microbiome viewed across age and geography. *Nature* 2012;**486**(7402):222-7.
doi: 10.1038/nature11053.
42. Maldonado-Gomez MX, Martinez I, Bottacini F, O'Callaghan A, Ventura M, van
Sinderen D, et al.; Stable Engraftment of *Bifidobacterium longum* AH1206 in the Human Gut
Depends on Individualized Features of the Resident Microbiome. *Cell Host Microbe*
2016;**20**(4):515-526. doi: 10.1016/j.chom.2016.09.001.
43. Montassier E, Valdes-Mas R, Batard E, Zmora N, Dori-Bachash M, Suez J, et al.;
Probiotics impact the antibiotic resistance gene reservoir along the human GI tract in a person-

specific and antibiotic-dependent manner. *Nat Microbiol* 2021;**6**(8):1043-1054. doi:
10.1038/s41564-021-00920-0.

44. Odamaki T, Horigome A, Sugahara H, Hashikura N, Minami J, Xiao JZ, et al.;
Comparative Genomics Revealed Genetic Diversity and Species/Strain-Level Differences in
Carbohydrate Metabolism of Three Probiotic Bifidobacterial Species. *Int J Genomics*
2015;**2015**:567809. doi: 10.1155/2015/567809.

45. Ng KM, Ferreyra JA, Higginbottom SK, Lynch JB, Kashyap PC, Gopinath S, et al.;
Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens.
Nature 2013;**502**(7469):96-9. doi: 10.1038/nature12503.

46. Egan M, Motherway MO, Kilcoyne M, Kane M, Joshi L, Ventura M, et al.; Cross-
feeding by *Bifidobacterium breve* UCC2003 during co-cultivation with *Bifidobacterium*
bifidum PRL2010 in a mucin-based medium. *BMC Microbiol* 2014;**14**:282. doi:
10.1186/s12866-014-0282-7.

47. Kheadr E, Dabour N, Le Lay C, Lacroix C, Fliss I; Antibiotic susceptibility profile of
bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress. *Antimicrob Agents*
Chemother 2007;**51**(1):169-74. doi: 10.1128/AAC.00261-06.

48. Lynn MA, Ryan FJ, Tee YC, Benson SC, Lynn DJ; Protocol to assess the impact of
early-life antibiotic exposure on murine longevity. *STAR Protoc* 2022;**3**(1):101220. doi:
10.1016/j.xpro.2022.101220.

49. Lynn MA, Tumes DJ, Choo JM, Sribnaia A, Blake SJ, Leong LEX, et al.; Early-Life Antibiotic-Driven Dysbiosis Leads to Dysregulated Vaccine Immune Responses in Mice. *Cell Host Microbe* 2018;**23**(5):653-660 e5. doi: 10.1016/j.chom.2018.04.009.
50. McMullan B, Cooper C, Spotswood N, James R, Jones C, Konecny P, et al.; Antibiotic prescribing in neonatal sepsis: an Australian nationwide survey. *BMJ Paediatr Open* 2020;**4**(1):e000643. doi: 10.1136/bmjpo-2020-000643.
51. Cunningham M, Azcarate-Peril MA, Barnard A, Benoit V, Grimaldi R, Guyonnet D, et al.; Shaping the Future of Probiotics and Prebiotics. *Trends Microbiol* 2021;**29**(8):667-685. doi: 10.1016/j.tim.2021.01.003.
52. Henrick BM, Rodriguez L, Lakshmikanth T, Pou C, Henckel E, Arzoomand A, et al.; Bifidobacteria-mediated immune system imprinting early in life. *Cell* 2021;**184**(15):3884-3898 e11. doi: 10.1016/j.cell.2021.05.030.
53. Glover JS, Ticer TD, Engevik MA; Characterizing the mucin-degrading capacity of the human gut microbiota. *Sci Rep* 2022;**12**(1):8456. doi: 10.1038/s41598-022-11819-z.
54. Cani PD, Depommier C, Derrien M, Everard A, de Vos WM; Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms. *Nat Rev Gastroenterol Hepatol* 2022;**19**(10):625-637. doi: 10.1038/s41575-022-00631-9.

55. Atarashi K, Tanoue T, Ando M, Kamada N, Nagano Y, Narushima S, et al.; Th17 Cell Induction by Adhesion of Microbes to Intestinal Epithelial Cells. *Cell* 2015;**163**(2):367-80. doi: 10.1016/j.cell.2015.08.058.
56. Szczesnak A, Segata N, Qin X, Gevers D, Petrosino JF, Huttenhower C, et al.; The genome of th17 cell-inducing segmented filamentous bacteria reveals extensive auxotrophy and adaptations to the intestinal environment. *Cell Host Microbe* 2011;**10**(3):260-72. doi: 10.1016/j.chom.2011.08.005.
57. Rausch P, Kunzel S, Suwandi A, Grassl GA, Rosenstiel P, Baines JF; Multigenerational Influences of the Fut2 Gene on the Dynamics of the Gut Microbiota in Mice. *Front Microbiol* 2017;**8**:991. doi: 10.3389/fmicb.2017.00991.
58. Thorman AW, Adkins G, Conrey SC, Burrell AR, Yu Y, White B, et al.; Gut Microbiome Composition and Metabolic Capacity Differ by FUT2 Secretor Status in Exclusively Breastfed Infants. *Nutrients* 2023;**15**(2). doi: 10.3390/nu15020471.
59. Omata Y, Aoki R, Aoki-Yoshida A, Hiemori K, Toyoda A, Tateno H, et al.; Reduced fucosylation in the distal intestinal epithelium of mice subjected to chronic social defeat stress. *Sci Rep* 2018;**8**(1):13199. doi: 10.1038/s41598-018-31403-8.
60. Plottel CS, Blaser MJ; Microbiome and malignancy. *Cell Host Microbe* 2011;**10**(4):324-35. doi: 10.1016/j.chom.2011.10.003.

61. Qin Y, Havulinna AS, Liu Y, Jousilahti P, Ritchie SC, Tokolyi A, et al.; Author
Correction: Combined effects of host genetics and diet on human gut microbiota and incident
disease in a single population cohort. *Nat Genet* 2024;**56**(3):554. doi: 10.1038/s41588-024-
01693-y.
62. Zhernakova DV, Wang D, Liu L, Andreu-Sanchez S, Zhang Y, Ruiz-Moreno AJ, et al.;
Host genetic regulation of human gut microbial structural variation. *Nature*
2024;**625**(7996):813-821. doi: 10.1038/s41586-023-06893-w.
63. Nordgren J, Svensson L; Genetic Susceptibility to Human Norovirus Infection: An
Update. *Viruses* 2019;**11**(3). doi: 10.3390/v11030226.

FIGURES AND TABLES

Fig. 1: *Fut2* affects the faecal microbiota of male mice. (A) Breeding and co-housing design. *Fut2*^{HET} mice were bred to produce *Fut2*^{WT} and *Fut2*^{KO} littermates. Genotypes were co-housed until weaning (~3 weeks), where mice were separated by sex and *Fut2* genotype until 6 weeks of age. (B) Taxa bar plot of the faecal microbiota of *Fut2*^{WT} and *Fut2*^{KO} mice, also stratified by sex. (C) Non-metric multidimensional scaling (NMDS) plot of faecal microbiota showing significant separation between *Fut2*^{WT} and *Fut2*^{KO} male mice but not *Fut2*^{WT} and *Fut2*^{KO} female mice. Significance: Permutational multivariate ANOVA. (D) The prevalence and mean relative abundance of faecal taxa in *Fut2*^{WT} and *Fut2*^{KO} male mice, highlighting the “core” taxa present in ≥95% of mice and at a mean relative abundance of ≥0.01%. (E) Venn diagram of core taxa shared or different between *Fut2*^{WT} and *Fut2*^{KO} male mice. (F) Faecal taxa significantly different between *Fut2*^{WT} and *Fut2*^{KO} male mice. Significance: Linear discriminant analysis (LDA) Effect Size (LEfSe).


Fig. 2: *Fut2* affects the intestinal microbiota. (A) Taxa bar plot of the intestinal mucosal microbiota of *Fut2*^{WT} and *Fut2*^{KO} mice. (B) Non-metric multidimensional scaling (NMDS) plots of *Fut2*^{WT} and *Fut2*^{KO} intestinal mucosal microbiota. Significance: Permutational multivariate ANOVA. (C) Taxa significantly different between *Fut2*^{WT} and *Fut2*^{KO} intestinal mucosal tissue. Significance: Linear discriminant analysis (LDA) Effect Size (LEfSe). No taxa differed between *Fut2*^{WT} and *Fut2*^{KO} proximal small intestine.

Fig. 3: 2'-Fucosyllactose modifies the faecal microbiota *in vitro* and enhances growth of α(1,2)-fucosylated glycan utilising bacteria. (A) Taxa bar plot of the faecal microbiota of *Fut2*^{WT} mice following anaerobic growth either with or without 2'-Fucosyllactose (2'-FL).

(B) Non-metric multidimensional scaling (NMDS) plot of faecal microbiota following anaerobic growth with or without 2'-FL. Significance: Permutational multivariate ANOVA. (C) Taxa significantly different between *Fut2*^{WT} faecal samples following anaerobic growth with or without 2'-FL. Significance: Linear discriminant analysis (LDA) Effect Size (LEfSe). (D) Comparison of colonies relative abundance of identified colonies following anaerobic growth with or without 2'-FL. **E. coli* or *Shigella*. (E) Optical density (OD) following *Fut2*^{WT} faecal bacteria cultured with or without 2'-FL. (F) OD of *Fut2*^{WT} or *Fut2*^{KO} faecal bacteria following growth with 2'-FL. OD normalised to growth in media without 2'-FL.

Fig. 4: *Bifidobacterium infantis*, but not *B. breve* or *B. bifidum*, persists longer in *Fut2*^{WT} mice following antibiotic pre-exposure. (A) Experimental design. (B) Persistence of detectable *Bifidobacterium* species in stool following antibiotic pre-exposure. Significance: log-rank test. (C) Bacterial copies of *Bifidobacterium* species in stool following antibiotic pre-exposure. Significance: T-test of area under the curve. (D) Bacterial copies of *B. infantis* in intestinal tissue mucosa following antibiotic pre-exposure. Significance: Mann-Whitney U test.

Fig. 5: *Bifidobacterium infantis* persists longer in *Fut2*^{KO} mice without antibiotic pre-treatment. (A) Experimental design. (B) Persistence of gavaged *Bifidobacterium infantis* in stool without antibiotic pre-treatment. Significance: log-rank test. (C) Bacterial copies of *B. infantis* in stool without antibiotic pre-treatment. Significance: T-test of area under the curve.









Figure 3


[Click here to access/download;Figure;Figure 3_Final.png](#)




A




B



C





[Click here to access/download](#)

Supplemental Material

Supplementary information_Final.docx

